

Press Release

June 26, 2026

**Regulatory Approval of CANALIA® Tablets,
type 2 diabetes mellitus treatment agent in Thailand**

Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada; hereinafter "Tanabe Pharma") announced today that on June 24th, 2026, Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (hereinafter "MTTH") received Marketing Authorization for CANALIA® Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor TENELIA® Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU® Tablets (generic name: canagliflozin) in Thailand. The approval is for an indication of type 2 diabetes mellitus.

It is estimated that there are approximately 6.4 million adult diabetes patients in Thailand in 2024, and this trend is expected to continue.


MTTH has been selling products in the cardiovascular and metabolic disease areas in Thailand, which has one of the largest pharmaceutical markets in the ASEAN region, alongside Indonesia. Leveraging that foundation, taking this opportunity, MTTH will contribute to treatment of patients with type 2 diabetes mellitus.

Under our MISSION, "Creating hope for all facing illness," Tanabe Pharma will continue to strive to provide pharmaceuticals that address unmet medical needs through in-house development and partnerships with other companies, delivering these options to patients.

<p><i>Contact:</i> Tanabe Pharma Corporation CEO Office Communication Group +81-6-6205-5119</p>

■ About CANALIA® Tablets

CANALIA® Tablets is a combination drug that contains a selective DPP-4 inhibitor and a SGLT2 inhibitor. Both TENELIA® Tablets and CANAGLU® Tablets are type 2 diabetes mellitus treatment agents originally discovered by Tanabe Pharma in Japan. CANALIA® Tablets, a combination drug incorporating the above two constituents, is an orally-administered (once daily) agent that lowers blood-glucose levels based on two different mechanisms of action: inhibiting DPP-4 and



thereby increasing insulin release according to blood glucose levels; and inhibiting SGLT2 and thereby promoting excretion of glucose into urine.

■ About Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (MTTH)

Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (MTTH) was founded as a wholly-owned subsidiary of Tanabe Pharma in Thailand in 2016. Along with Indonesia, Thailand has one of the largest pharmaceutical markets in the ASEAN region. MTTH sells many products for lifestyle-related diseases such as HERBESSER[®], TANATRIL[®], TENELIA[®] and CANAGLU[®]. MTTH will expand its central nervous system pipeline with REAGILA[®], a medication for schizophrenia, bipolar disorder and adjunctive therapy for major depressive disorder, and REMLEAS[®], treatment for tardive dyskinesia.

The company name is scheduled to be changed to "Tanabe Pharma (Thailand) Co., Ltd." in December 2026.